Skip to main content
. 2024 Jan 18;15:1307558. doi: 10.3389/fimmu.2024.1307558

Figure 3.

Figure 3

C3a, C5a and lyso-Gb3 concentrations in the circulation of FD patients with ADA-negative/positive status. (A–D) C3a, (E–H) C5a and (I–L) lyso-Gb3 concentrations (ng/ml) in serum from ADA-negative (n=6) or ADA-positive (n=11) (A, E, I) patients, who were either treatment-naiüve (n=17) or (B, F, J) received ERT (n=17). (C, G, K) ADA-negative (n=6) or (D, H, L) ADA-positive (n=11) FD patients before (V0) or under ERT (V1). Red lines denote patients with missense mutations. Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by unpaired t-test (A, B, E, F, I, J) or paired t-test (C, D, G, H, K, L). Data in (A, B, E, F, I, J) are shown as mean + SEM. *p<0.05; ***p<0.001.